<DOC>
	<DOCNO>NCT02017275</DOCNO>
	<brief_summary>PANDA III seek investigate safety efficacy PLGA-polymer electro-grafting base layer sirolimus-eluting stent ( SES ) versus PLA-polymer SES 12 month follow-up .</brief_summary>
	<brief_title>Comparison BuMA eG Based BioDegradable Polymer Stent With EXCEL Biodegradable Polymer Sirolimus-eluting Stent `` Real-World '' Practice</brief_title>
	<detailed_description>The BuMA stent ( SINOMED , Beijing , China ) novel biodegradable PLGA polymer sirolimus-eluting stent ( SES ) , design add electro-grafting ( eG ) base layer polymer stainless steel stent strut.The eG layer secure adhesion biodegradable PLGA coat result interdigitation , PLGA coat ensure 100 % drug release within 30 days.The initial investigation show high strut coverage rate BuMA stent Xience V stent 3 month follow-up . Moreover , early vascular heal drug-eluting stent implantation may reduce incidence stent thrombosis follow-up potentially shorten dual antiplatelet therapy duration . Therefore , perform randomize trial investigate 12 month target lesion failure BuMA EXCEL stent , elute drug sirolimus , however different biodegradable polymer carrier .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chlorhexidine</mesh_term>
	<mesh_term>Chlorhexidine gluconate</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>The patient must â‰¥18 age ; Symptomatic ischemic heart disease and/or objective evidence myocardial ischemia include chronic stable coronary artery disease , acute coronary syndrome include nonSTelevation STelevation myocardial infarction ; Acceptable candidate CABG ; The patient willing comply specify followup evaluation ; Patients agree accept followup visit . Patients understand study objective psychologically linguistically show sufficient compliance study protocol . Patients present acceptance risk benefit describe informed consent form . At least one lesion diameter stenosis &gt; 50 % suitable coronary stent implantation vessel reference diameter range 2.5 mm 4.0 mm ; Pregnant nursing patient plan pregnancy period 1 year follow index procedure . Patient medical illness ( e.g. , cancer , know malignancy , congestive heart failure , organ transplant recipient candidate ) know history substance abuse ( alcohol , cocaine , heroin etc . ) may cause noncompliance protocol , confound data interpretation associate limited life expectancy ( i.e. , less 1 year ) ; Patient know hypersensitivity contraindication aspirin , heparin , clopidogrel/ticlopidine , stainless steel alloy , cobalt chromium , rapamycin , styrenebutylenesstyrene polylactic acid ( PLA ) polymer , and/or contrast sensitivity adequately premedicated ; Any significant medical condition Investigator 's opinion may interfere patient 's optimal participation study ; Currently participate another investigational drug device study patient inclusion another investigational drug device study followup .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>